Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.

Herantis Pharma logo

Find us on LinkedIn


  • Highlight

    Minutes of Herantis Pharma Plc’s Annual General Meeting of shareholders April 24, 2024.

  • Highlight

    Watch Herantis Pharma’s Full Year 2023 webcast here

Latest news and releases